© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Capreomycin sulfate’s story began deep in the soil, from a microbe discovered decades ago. Tuberculosis, especially strains that laugh in the face of the standard treatments, has pressed doctors and scientists to look far and wide. During the 1960s, the world saw a steady rise in drug-resistant TB. Researchers pulled out all stops, and through sheer stubborn effort, capreomycin emerged as a promising tool. The joy of an injectable weapon against “tough” TB fueled interest across continents. This antibiotic didn’t win much popularity among patients because of the need for injections, but it became a steady piece of the puzzle for clinicians on the frontlines of MDR-TB (multidrug-resistant tuberculosis).
Today, talk of capreomycin sulfate generally refers to its use as a lyophilized powder that, after reconstitution, is administered intramuscularly. The product carries a long laundry list of chemical names (through the years, some called it Capricorn, Capra, or Dihydrostreptomycin B, and labs still toss around names like ‘Lakapre’), but the essential point is this: unlike most run-of-the-mill antibiotics, it isn’t from the typical chemical shelf. Instead, its structure speaks of a nonribosomal peptide nature, with peptide bonds folding into a cyclic heptapeptide. You don’t get capreomycin by stirring two powders together. Its biosynthesis traces back to Streptomyces capreolus, an actinobacterium that few outside the field would recognize. Processing involves deep fermentation, extraction, and purification — a dance of industrial microbiology that highlights just how much effort goes into such a ‘simple’ white powder.
Looking at capreomycin sulfate from a technical angle, it’s hard not to feel the weight of its complex chemistry. The molecule sports multiple amino and hydroxy groups, which draw in water like a sponge, imparting its high solubility in aqueous media. The sulfate salt form used clinically stabilizes this tendency and makes dosing more predictable. The white-to-cream powdered look may not hint at much, but the chemical backbone is anything but simple. Capreomycin doesn’t dissolve easily in organic solvents but jumps right into water-based solutions, helpful for injectables and ensuring the whole dose lands where required. Quality standards keep a tight leash on impurities and moisture, but the risk of degradation hovers if handled outside well-controlled conditions.
Producing capreomycin sulfate takes more than mixing reagents; it’s a technical undertaking that can make or break supply chains. Fermentation must run under precise conditions — temperature, pH, aeration — since even a mild slip spells disaster for yields or purity. Extraction involves solvent partitioning and repeated filtration. Even after crystallization and drying, the compound needs vigilant protection from humidity and heat. Over the years, scientists have poked and prodded at the molecule, aiming to craft analogues with greater power or fewer side effects. Chemical modifications, like acylation or methylation, alter how the compound binds to bacterial ribosomes — but few can dislodge the original in terms of clinical utility. Research teams keep one eye on ways to simplify or speed up fermentation, aiming to ensure this drug isn’t just for wealthier health systems.
Working with capreomycin sulfate isn’t a job for the careless. Handling the powder requires respect for respiratory risks; both pharmacists and lab workers don masks and gloves, and facilities rely on careful air filtration and storage under low humidity. Precise labeling speaks to the potential dangers of misuse. Past experience has shown that patients receiving capreomycin can develop hearing loss, kidney injury, and allergic reactions — a sobering fact that pushes any responsible system to monitor closely and educate persistently. The drug’s restricted use today spotlights the clinical need balanced with a respect for possible harm.
In my work with infectious diseases, capreomycin appeared most often in teams wrestling with challenging MDR-TB cases. It was rarely a first choice, but would come to the rescue when other regimens had failed or resistance limited options. Doctors, especially in resource-limited settings, depended on it for patients who could still withstand tough side effects — for them, the benefit often outweighed the risk. Hospitals serving migrants or vulnerable communities kept it as a back-pocket option. Outside human medicine, some tried to repurpose capreomycin for laboratory research into bacterial protein synthesis. Researchers treated it as a probe for how antibiotics twist the function of the ribosome, guiding new drugs that might dodge resistance.
Science has never stopped questioning capreomycin sulfate’s darkest downsides. Clinical literature marks cases of ototoxicity, nephrotoxicity, and tolerance issues. These don’t just show up on academic graphs; they hit real patients, sometimes forcing an early halt to life-saving therapy. Regulatory bodies require close monitoring, with blood workups and hearing tests as common fare. New studies aim not only to track adverse events but to uncover genetic or biochemical reasons why some suffer more than others. Innovative drug-delivery methods, including long-acting formulations, might someday trim the risks, but we’re not there yet. There is talk among global TB networks about phasing out capreomycin in favor of drugs with better safety profiles. That’s a sobering prospect for places where the alternatives cost more or still face distribution hurdles.
The future of capreomycin sulfate ties closely to the shifting landscape of infectious disease control. Progress in molecular biology and genomics shines a light on just how bacteria evolve resistance, offering hope for next-generation derivatives or smarter combinations that reawaken the drug’s strengths without unleashing so much collateral damage. Funding for research hinges on global priorities, which swing between new antibiotic discovery and efforts to strengthen drug stewardship. The day may come when capreomycin returns to the lab shelf rather than the pharmacy counter, but for now, it stands as both a symbol of past innovation and a challenge to do better. A world facing rising antibiotic resistance can’t afford complacency, and capreomycin sulfate — burdens and all — demands honest conversation about access, safety, and ethical use. Whether through improved fermentation technology, emerging modifications with less toxicity, or refined clinical guidelines, its story signals that fighting drug-resistant infections takes much more than chemistry textbooks and production lines; it takes vigilance, patience, and a refusal to give up on hard problems.
Capreomycin sulfate stands out in medicine for one solid reason—its role in fighting off tough cases of tuberculosis. Not the easy kind either. Doctors often turn to this drug when they run up against strains of TB that refuse to back down after the usual treatment. I’ve worked in hospital pharmacy teams where we’ve faced this scenario. Regular antibiotics hit a wall and, as a result, families get stuck in waiting rooms with little hope until more potent options like capreomycin enter the picture.
Patients with multidrug-resistant TB, commonly called MDR-TB, rely on capreomycin. These patients come from all walks of life, but you see more cases in communities with little routine medical access, or where TB hasn’t been managed well for years. The Centers for Disease Control and Prevention estimates nearly half a million MDR-TB cases appear worldwide each year. For those folks, capreomycin isn’t just another medicine on the list; it can spell the difference between recovery and a downward slide.
Capreomycin works by stopping the bacteria’s ability to make the proteins it needs to survive. It doesn’t act as a first-line treatment. If standard antibiotics don’t do the trick, then healthcare providers bring out the capreomycin. It comes as a powder that gets dissolved and injected deep into muscle, which means patients often need to visit clinics or hospitals for treatment. In my experience, that can feel tough for people living in remote places, but the drug’s impact can make the trip worthwhile.
No medicine arrives without headaches. Capreomycin brings its own set of worries, from kidney problems to hearing loss for some patients. Experienced clinicians monitor these risks closely. Anyone considering this drug needs regular check-ups to measure kidney function and assess hearing. One patient in my care developed ringing in her ears after a couple months—she and her family grappled with the fear that the cure might create new difficulties. This risk only underscores the need for trustworthy care and open conversations between care teams and patients.
Drug resistance in TB isn’t rare anymore. People travel, borders blur, and bacteria adapt quickly. Every missed dose, every incomplete prescription, opens the door a little wider for TB bugs to shape-shift past standard treatments. Capreomycin exists because solutions to these new challenges don’t spring up overnight. As resistance grows, doctors look for medicines that can outsmart even the cleverest germs.
A stronger system for detection and strict adherence to treatment can bring down the need for drugs like capreomycin. Community outreach programs, patient education, and access to regular monitoring, especially in low-resource areas, all help. New drug development remains urgent, but using what’s already on hand wisely matters too. I’ve seen the difference it makes when teams don’t just hand out medicine, but sit down with families to map out treatment schedules and explain side effects. Encouraging full completion of therapy keeps resistance down and medicines effective for years to come.
People who have taken Capreomycin Sulfate often start noticing some changes in how they feel. This antibiotic, usually given by injection, helps fight tough tuberculosis infections that haven’t responded to other options. Like any powerful medicine, it doesn’t always play nice with every part of the body. If you or someone close to you uses Capreomycin Sulfate, you’ll want to watch out for a few things.
Ears can take the brunt with this drug. Some people develop ringing, buzzing, or other strange sounds. My friend’s father needed this medication a few years back and described muffled hearing similar to water being trapped in the ears. The risk grows with longer or higher doses. The reason comes down to how Capreomycin can build up in the fluid around the tiny hearing and balance organs in the ear, sometimes leading to lasting damage.
Doctors worry about kidneys whenever Capreomycin comes into play. Some users see changes in their urine. They might notice less coming out, or swelling in feet and ankles. If I look at case studies, blood tests linked to Capreomycin sometimes show rising creatinine and urea, telling us the kidneys aren’t clearing waste like they should. The National Library of Medicine points out that careful monitoring of kidney function helps catch this early, but that means bloodwork, not just waiting for symptoms.
The shot itself can pack a punch. Many complain about stiff, sore muscles for days. Redness, irritation, and even small lumps under the skin sometimes arise. This often shows up on the buttock or thigh, wherever the nurse delivered the dose. My experience working in a small hospital taught me to rotate injection sites and use proper technique to keep this from getting tough to manage.
Some patients start feeling dizzy or notice it’s tougher to keep their balance. The medication affects not just hearing but other nerves too. Numbness, tingling, and even twitching in toes or fingers sometimes turn up. These signals shouldn’t be ignored, since nerve issues might become permanent with long exposure.
Capreomycin sometimes brings on rashes or itchiness. My immunology professor used to say, “If you spot a red, itchy patch, mention it.” A rapid heartbeat, fever, or trouble breathing can hint at rare but serious allergic reactions. People may also feel sick to their stomach or even throw up. Appetite might drop off. I’ve seen fatigue and confusion pop up, especially in older folks or those with other illnesses.
Patients get safer results if healthcare teams keep a close eye on symptoms and do regular blood checks. Hydration helps kidneys flush out the drug. Lowering the dose or spacing out injections might ease nerve and hearing risks. Anyone noticing changes should speak up early—there’s no glory in suffering in silence.
Capreomycin saves lives when nothing else works against stubborn tuberculosis. To stay safe, keep the conversation open between patients and providers, and watch out for the warning signs.
Capreomycin sulfate plays a crucial role in treating certain stubborn infections, like multi-drug resistant tuberculosis. This medication isn’t some tablet you can swallow at home along with your morning coffee. Instead, it’s given through injection – and getting that right stands out as a real skill.
For people who’ve faced tuberculosis that laughs in the face of the usual drugs, capreomycin sulfate steps in. From what I’ve seen, this medication often comes as a powder. The healthcare worker mixes this powder with a clear liquid, then draws it up into a syringe. The full dose finds its way into the body either through a deep muscle injection (usually the buttock) or, less commonly, an intravenous line. It’s rarely a one-off event. Treatments can drag on for months, and daily injections place strain not just on the patient’s body but also on the healthcare system delivering them.
Anyone who’s had an injection knows it doesn’t always feel great. Soreness, swelling, or even a lump at the site can grow worse the longer treatment continues. There’s more lurking beneath the surface, though. Capreomycin sulfate can put stress on kidneys and hearing. As a result, regular blood tests track kidney function, and hearing tests catch early signs of trouble. I’ve had patients who dreaded not just the pain of the needle but also the uncertainty hanging over their test results.
Administering this drug safely isn’t something you learn from watching a quick video online. Healthcare workers need steady hands. Clinics need a reliable supply not just of the drug, but also fresh needles, proper disinfectants, personal protective gear, and clear protocols. Stock-outs, rushed staff, or poor sanitation—it all puts patients at risk for infection at the injection site or the spread of disease.
No one likes lining up for weeks or months on end, arm or leg exposed, bracing for another round. Fatigue, frustration, and even transport costs chip away at patients. Sometimes people decide the hassle isn’t worth it and drop out of treatment. This only fuels more resistant infections. Programs that provide transport stipends, emotional support, or education hint at a better way. I’ve seen patients hang in there longer when clinics build real relationships rather than simply delivering shots.
In places where tuberculosis hits hardest, high-quality healthcare often feels miles away. Governments and global health groups often talk about training more nurses and investing in cold storage and logistics just to keep these medications available and safe. Community health workers, if properly prepared, can extend a lifeline to people far from big hospitals. A world where treatment meets people where they live doesn’t just sound nice—it determines whether some patients actually finish the fight against deadly infections.
Capreomycin sulfate can bring hope to people facing tough cases of tuberculosis, especially the drug-resistant kind. Spending years interviewing infectious disease doctors and learning from patients who live through these treatments, I’ve seen how potent and rough this antibiotic can be. Its risks are not just theory; they show up in real people’s lives. You can’t take Capreomycin lightly or without careful planning.
Anyone considering Capreomycin should know about the risk to the kidneys. The trouble often starts quietly—rising creatinine, a little swelling, less urine output—then bells go off when the damage turns obvious. Age doesn’t do patients any favors here. Older adults, folks with a history of kidney trouble, or people juggling other heavy-duty medications find themselves at a higher tipping point for toxicity. Dosing needs close review, and most folks do better with regular kidney function monitoring. I’ve seen more than one patient end up hospitalized after missing this step. The US Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) both warn about this, and with good reason.
Deafness or ringing ears sounds like something you only worry about with lifetime exposure to loud noise, but Capreomycin can do it after only days or weeks. Sometimes it creeps in subtly—a new ringing, muffled conversations, struggling in noisy rooms. The higher the dose and longer the treatment, the greater the risk. Kids and older adults tend to suffer more. Audiometric testing before and during therapy isn’t a formality; it’s a lifeline. Several sources, including the American Thoracic Society, flag ototoxicity as a reason to reconsider treatment if symptoms start.
Capreomycin shares a risk of serious allergic reactions with other injectable antibiotics. Rashes, fevers, bronchospasm, even anaphylaxis can strike, sometimes without any past warning. If someone has reacted badly to similar drugs—think streptomycin or amikacin—it pays to be extra cautious. Past allergy isn’t just a red-flag on a chart, it’s a reason to look hard at alternatives or prepare for rapid treatment of reactions.
Capreomycin doesn’t just stop at the kidneys or ears. Hypokalemia and hypomagnesemia (dangerously low potassium and magnesium) pop up enough to put lives on the line, causing confusion, muscle cramps, and heart rhythm problems. For anyone with muscle diseases like myasthenia gravis, Capreomycin can make weakness worse. These aren’t symptoms you brush off or hope will pass.
Real-world TB treatment rarely involves just one drug. Mixing Capreomycin with other nephrotoxic or ototoxic drugs—like aminoglycosides—raises the stakes. Each new pill or injection adds its own risk side-effects. Doctors usually try to stagger doses and avoid overlap, but sometimes you don’t have much choice. It takes teamwork between the patient, nurse, and doctor to track what’s happening.
All these precautions don’t mean Capreomycin has no place in care. Tuberculosis that resists easier options sometimes leaves doctors with tough choices. Early bloodwork, frequent hearing checks, and honest discussions about risk versus benefit keep patients safer. Some clinics now include genetic testing to see who could react more severely, and digital reminders help flag symptoms and missed appointments. People deserve fair warning and close follow-up, because these side effects can linger till long after the TB clears.
Pregnancy brings enough challenges without having to worry about whether a tuberculosis antibiotic will harm your baby. Capreomycin sulfate isn’t an everyday drug—doctors usually reach for it when TB refuses to back down to other treatments. This makes the question of using it during pregnancy or breastfeeding more than a theoretical debate. In countries where drug-resistant TB wreaks havoc, the stakes jump even higher. For women on the front lines—patients and prescribers alike—it’s never just a black-and-white decision.
Capreomycin came out decades ago, before the demands of pregnancy safety trials landed in regulatory rulebooks. No one rushed to test this drug on pregnant women; researchers have mostly relied on animal studies and case reports. In rats, high doses led to fetal harm, including hearing loss. Human data dribbles in the form of case series and global TB program data, and problems in babies—like deafness—keep specialists up at night. Though the WHO lists capreomycin as possibly unsafe in pregnancy, clinicians sometimes must weigh imperfect evidence against the grim prospects of untreated TB.
Talking to infectious disease specialists, I’ve learned that untreated or undertreated TB doesn’t just risk the mother’s life—it threatens the baby’s safety, too. TB in pregnancy, especially the drug-resistant form, leads to higher rates of miscarriage, low birth weight, and even transmission of the disease to the newborn. The CDC and WHO both recommend treatment for all pregnant women with active TB, adjusting the regimen based on what’s possible and safe. Most steer clear of capreomycin where other, better-studied drugs might work, but drug resistance leaves few alternatives.
Babies absorb almost everything their mother takes. With capreomycin, no one has nailed down how much passes into breast milk, but like other aminoglycoside antibiotics, it carries risks. Hearing damage and kidney problems top the list of worries, both for the mother and baby. In practice, doctors often recommend formula feeding if capreomycin becomes unavoidable, though this isn’t always possible in places where clean water or formula run short. If a mother continues to breastfeed, her care team must monitor the newborn closely for side effects, especially hearing and urine output.
Facing a resistant TB diagnosis during pregnancy means balancing hope and fear. Trust often hinges on honest conversations. There’s no glossing over the fact that almost every TB drug brings risks in pregnancy—but untreated infection leaves mothers and babies in far greater danger. The World Health Organization calls for individualized case reviews and ethical reflection. Doctors must explain unknowns about capreomycin, discuss what’s happened in rare cases, and put the latest evidence on the table before making decisions together with each family.
Stronger safety data would remove a ton of worry. International TB programs could collect more real-world pregnancy outcomes and make those results public. Research should focus on alternative drug combinations with a better track record in pregnant and breastfeeding women. In the meantime, training every provider to lift up women’s voices in decision-making will keep medical care safer for both mothers and babies caught up in a TB crisis.
| Names | |
| Preferred IUPAC name | Capreomycin sulfate |
| Other names |
Capreomycin Capastat Sulfate Capreomicina Capreomycine Capreomycinsulfat Capreomycinum |
| Pronunciation | /kæpˌriː.əˈmaɪ.sɪn ˈsʌl.feɪt/ |
| Identifiers | |
| CAS Number | 1405-37-4 |
| Beilstein Reference | 1728953 |
| ChEBI | CHEBI:3137 |
| ChEMBL | CHEMBL1200987 |
| ChemSpider | 11446704 |
| DrugBank | DB00411 |
| EC Number | 215-077-6 |
| Gmelin Reference | 67654 |
| KEGG | D00341 |
| MeSH | D002196 |
| PubChem CID | 60750 |
| RTECS number | GK5050000 |
| UNII | 140L5S44EH |
| UN number | UN3077 |
| Properties | |
| Chemical formula | C25H44N14O8·H2SO4 |
| Molar mass | Molar mass: 1425.5 g/mol |
| Appearance | White to pale yellow or pale greenish-yellow crystalline powder |
| Odor | Odorless |
| Density | 1.53 g/cm3 |
| Solubility in water | Freely soluble in water |
| log P | -5.2 |
| Acidity (pKa) | pKa 7.4 |
| Basicity (pKb) | 8.62 |
| Magnetic susceptibility (χ) | -84.0×10⁻⁶ cm³/mol |
| Dipole moment | 0.0 D |
| Pharmacology | |
| ATC code | J04AB30 |
| Hazards | |
| Main hazards | Causes serious eye irritation. May cause respiratory irritation. |
| GHS labelling | GHS05, GHS07, GHS08 |
| Pictograms | GHS06,GHS08 |
| Signal word | Warning |
| Hazard statements | H302 + H332: Harmful if swallowed or if inhaled. |
| Precautionary statements | Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Avoid breathing dust/fume/gas/mist/vapors/spray. Wear protective gloves/protective clothing/eye protection/face protection. |
| NFPA 704 (fire diamond) | NFPA 704: 2-3-1 |
| Autoignition temperature | 600°C (lit.) |
| Lethal dose or concentration | LD50 Intravenous - Mouse - 520 mg/kg |
| LD50 (median dose) | LD50 (median dose) of Capreomycin Sulfate: Mouse, intraperitoneal: 204 mg/kg |
| NIOSH | WF0525000 |
| PEL (Permissible) | 0.5 mg/m³ |
| REL (Recommended) | 1 g IM/IV once daily |
| IDLH (Immediate danger) | Unknown |
| Related compounds | |
| Related compounds |
Capreomycin Viomycin Streptomycin Kanamycin Amikacin |
